{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,30]],"date-time":"2026-08-30T01:53:49Z","timestamp":1788054829174,"version":"build-2784847793"},"reference-count":150,"publisher":"Ovid Technologies (Wolters Kluwer Health)","funder":[{"name":"National Science and Technology Major Project of China","award":["2024ZD0523400, 2024ZD0523404"],"award-info":[{"award-number":["2024ZD0523400, 2024ZD0523404"]}]},{"name":"Interdisciplinary Program of Shanghai Jiao Tong University","award":["YG2023ZD21"],"award-info":[{"award-number":["YG2023ZD21"]}]},{"name":"National Key Research and Development Program of China","award":["2023YFC2411802"],"award-info":[{"award-number":["2023YFC2411802"]}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["82570825, 82170727"],"award-info":[{"award-number":["82570825, 82170727"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["82100744"],"award-info":[{"award-number":["82100744"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Shanghai Research Center for Endocrine and Metabolic Diseases","award":["2022ZZ01002"],"award-info":[{"award-number":["2022ZZ01002"]}]}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":["CJASN"],"abstract":"<jats:p>Diabetic kidney disease (DKD) remains a major global health burden and the most common cause of ESKD. The therapeutic landscape has profoundly shifted from a glucocentric model to a multifaceted strategy focusing on the holistic management of cardiovascular-kidney-metabolic syndrome. This therapeutic paradigm is now anchored by four foundational pillars: renin-angiotensin-aldosterone system inhibitors, sodium-glucose cotransporter 2 inhibitors, glucagon-like peptide-1 receptor agonists, and non-steroidal mineralocorticoid receptor antagonists, which collectively target complementary pathogenic pathways to slow DKD progression and reduce cardiovascular morbidity. Despite these advances, a high residual risk persists, driving kidney disease research into novel therapeutic targets. A large body of mechanistic studies demonstrates the critical roles of genetic and epigenetic modifications, persistent metabolic dysfunction, and inflammatory and fibrotic processes in DKD pathogenesis. Consequently, emerging investigational therapies are focused on histone-modifying enzymes, drugs to restore metabolic\/lipid disorders, new anti-inflammatory and anti-fibrosis therapies, as well as stem cell\u2013based interventions for their regenerative and immunomodulatory potential. The future of DKD management hinges on the successful clinical translation of these novel therapeutic approaches, which will require overcoming challenges in clinical trial design alongside current therapies, patient stratification for different therapeutic regimens using predictive biomarkers, and the exploration of synergistic combination therapies to ultimately personalize treatment strategies and enhance long-term kidney outcomes.<\/jats:p>","DOI":"10.2215\/cjn.0000001053","type":"journal-article","created":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T16:01:30Z","timestamp":1773158490000},"update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":5,"title":["Current Landscape and Emerging Therapeutic Targets in Diabetic Kidney Disease"],"prefix":"10.2215","author":[{"given":"Shuai","family":"Hu","sequence":"first","affiliation":[{"name":"Department of Nephrology, Shanghai Sixth People's Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9756-1765","authenticated-orcid":false,"given":"Kyung","family":"Lee","sequence":"additional","affiliation":[{"name":"Department of Medicine\/Nephrology, Icahn School of Medicine at Mount Sinai, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John Cijiang","family":"He","sequence":"additional","affiliation":[{"name":"Department of Medicine\/Nephrology, Icahn School of Medicine at Mount Sinai, New York, New York"},{"name":"Renal Section, James J Peters Veterans Affair Medical Center, Bronx, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Fan","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Shanghai Sixth People's Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2026,3,10]]},"reference":[{"issue":"8","key":"B1-20260402","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.2215\/CJN.11111016","article-title":"Diagnosis and management of type 2 diabetic kidney disease","volume":"12","author":"Doshi","year":"2017","journal-title":"Clin J Am Soc Nephrol."},{"issue":"10","key":"B2-20260402","doi-asserted-by":"crossref","first-page":"2864","DOI":"10.2337\/dc14-1296","article-title":"Diabetic kidney disease: a report from an ADA Consensus Conference","volume":"37","author":"Tuttle","year":"2014","journal-title":"Diabetes Care."},{"issue":"16","key":"B3-20260402","doi-asserted-by":"crossref","first-page":"1514","DOI":"10.1056\/NEJMoa1310799","article-title":"Changes in diabetes-related complications in the United States, 1990-2010","volume":"370","author":"Gregg","year":"2014","journal-title":"N Engl J Med."},{"issue":"1","key":"B4-20260402","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/s00125-018-4711-2","article-title":"Global trends in diabetes complications: a review of current evidence","volume":"62","author":"Harding","year":"2019","journal-title":"Diabetologia."},{"issue":"7","key":"B5-20260402","doi-asserted-by":"crossref","first-page":"e0158765","DOI":"10.1371\/journal.pone.0158765","article-title":"Global prevalence of chronic kidney disease - a systematic review and meta-analysis","volume":"11","author":"Hill","year":"2016","journal-title":"PLoS One."},{"issue":"2","key":"B6-20260402","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/j.kint.2022.05.012","article-title":"Molecular mechanisms and therapeutic targets for diabetic kidney disease","volume":"102","author":"Tuttle","year":"2022","journal-title":"Kidney Int."},{"issue":"24","key":"B7-20260402","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1056\/NEJMoa1811744","article-title":"Canagliflozin and renal outcomes in type 2 diabetes and nephropathy","volume":"380","author":"Perkovic","year":"2019","journal-title":"N Engl J Med."},{"key":"B8-20260402","doi-asserted-by":"crossref","first-page":"122275","DOI":"10.1016\/j.carbpol.2024.122275","article-title":"A graminan type fructan from achyranthes bidentata prevents the kidney injury in diabetic mice by regulating gut microbiota","volume":"339","author":"Si","year":"2024","journal-title":"Carbohydr Polym."},{"issue":"2","key":"B9-20260402","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1056\/NEJMoa2403347","article-title":"Effects of semaglutide on chronic kidney disease in patients with type 2 diabetes","volume":"391","author":"Perkovic","year":"2024","journal-title":"N Engl J Med."},{"issue":"20","key":"B10-20260402","doi-asserted-by":"crossref","first-page":"2001","DOI":"10.1056\/NEJMoa2501006","article-title":"Oral semaglutide and cardiovascular outcomes in high-risk type 2 diabetes","volume":"392","author":"McGuire","year":"2025","journal-title":"N Engl J Med."},{"issue":"23","key":"B11-20260402","doi-asserted-by":"crossref","first-page":"2219","DOI":"10.1056\/NEJMoa2025845","article-title":"Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes","volume":"383","author":"Bakris","year":"2020","journal-title":"N Engl J Med."},{"issue":"24","key":"B12-20260402","doi-asserted-by":"crossref","first-page":"2252","DOI":"10.1056\/NEJMoa2110956","article-title":"Cardiovascular events with finerenone in kidney disease and type 2 diabetes","volume":"385","author":"Pitt","year":"2021","journal-title":"N Engl J Med."},{"issue":"4S","key":"B13-20260402","first-page":"S117","article-title":"KDIGO 2024 clinical practice guideline for the evaluation and management of chronic kidney disease","volume":"105","year":"2024","journal-title":"Kidney Int."},{"issue":"1","key":"B14-20260402","doi-asserted-by":"crossref","first-page":"5062","DOI":"10.1038\/s41467-022-32477-9","article-title":"Reversal of the renal hyperglycemic memory in diabetic kidney disease by targeting sustained tubular p21 expression","volume":"13","author":"Al-Dabet","year":"2022","journal-title":"Nat Commun."},{"issue":"3","key":"B15-20260402","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1016\/j.kint.2024.10.031","article-title":"Epigenetic alterations and memory: key players in the development\/progression of chronic kidney disease promoted by acute kidney injury and diabetes","volume":"107","author":"Mimura","year":"2025","journal-title":"Kidney Int."},{"issue":"24","key":"B16-20260402","doi-asserted-by":"crossref","first-page":"2630","DOI":"10.1056\/NEJMe0804182","article-title":"Intensive glycemic control in the ACCORD and ADVANCE trials","volume":"358","author":"Dluhy","year":"2008","journal-title":"N Engl J Med."},{"issue":"6","key":"B17-20260402","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.2337\/dc19-1817","article-title":"Effects of intensive glycemic control on clinical outcomes among patients with type 2 diabetes with different levels of cardiovascular risk and hemoglobin A(1c) in the ADVANCE trial","volume":"43","author":"Tian","year":"2020","journal-title":"Diabetes Care."},{"issue":"2","key":"B18-20260402","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1161\/CIRCULATIONAHA.108.191305","article-title":"Intensive glycemic control and the prevention of cardiovascular events: implications of the ACCORD, ADVANCE, and VA diabetes trials: a position statement of the American Diabetes Association and a scientific statement of the American College of Cardiology Foundation and the American Heart Association","volume":"119","author":"Skyler","year":"2009","journal-title":"Circulation."},{"issue":"14","key":"B19-20260402","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1056\/NEJM199309303291401","article-title":"The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus","volume":"329","author":"Diabetes","year":"1993","journal-title":"N Engl J Med."},{"issue":"2","key":"B20-20260402","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1056\/NEJMoa0808431","article-title":"Glucose control and vascular complications in veterans with type 2 diabetes","volume":"360","author":"Duckworth","year":"2009","journal-title":"N Engl J Med."},{"issue":"24","key":"B21-20260402","doi-asserted-by":"crossref","first-page":"2545","DOI":"10.1056\/NEJMoa0802743","article-title":"Effects of intensive glucose lowering in type 2 diabetes","volume":"358","author":"Gerstein","year":"2008","journal-title":"N Engl J Med."},{"issue":"5S","key":"B22-20260402","first-page":"S1","article-title":"KDIGO 2022 clinical practice guideline for diabetes management in chronic kidney disease","volume":"102","year":"2022","journal-title":"Kidney Int."},{"issue":"4","key":"B23-20260402","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1053\/j.ajkd.2015.09.020","article-title":"Cost-effectiveness of simvastatin plus ezetimibe for cardiovascular prevention in CKD: results of the study of heart and renal protection (SHARP)","volume":"67","author":"Mihaylova","year":"2016","journal-title":"Am J Kidney Dis."},{"issue":"1","key":"B24-20260402","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1080\/0886022X.2021.1915799","article-title":"Efficacy of statins on renal function in patients with chronic kidney disease: a systematic review and meta-analysis","volume":"43","author":"Zhao","year":"2021","journal-title":"Ren Fail."},{"issue":"10","key":"B25-20260402","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1042\/CS20120352","article-title":"Association of dietary sodium intake with atherogenesis in experimental diabetes and with cardiovascular disease in patients with type 1 diabetes","volume":"124","author":"Tikellis","year":"2013","journal-title":"Clin Sci (Lond)."},{"issue":"1","key":"B26-20260402","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1038\/ijo.2014.72","article-title":"The incidence of albuminuria after bariatric surgery and usual care in Swedish Obese Subjects (SOS): a prospective controlled intervention trial","volume":"39","author":"Carlsson","year":"2015","journal-title":"Int J Obes (Lond)."},{"issue":"suppl 1","key":"B27-20260402","first-page":"S73","article-title":"Physical activity\/exercise and diabetes mellitus","volume":"26","author":"Zinman","year":"2003","journal-title":"Diabetes Care."},{"issue":"6","key":"B28-20260402","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1039\/c9tx00201d","article-title":"Cigarette smoke inhalation aggravates diabetic kidney injury in rats","volume":"8","author":"Jiang","year":"2019","journal-title":"Toxicol Res (Camb)."},{"key":"B29-20260402","doi-asserted-by":"crossref","first-page":"1631053","DOI":"10.3389\/fmed.2025.1631053","article-title":"Diabetic kidney disease: from pathogenesis to multimodal therapy-current evidence and future directions","volume":"12","author":"Zhang","year":"2025","journal-title":"Front Med (Lausanne)."},{"issue":"9","key":"B30-20260402","doi-asserted-by":"crossref","first-page":"1574","DOI":"10.2337\/dci23-0030","article-title":"Diabetic nephropathy: update on pillars of therapy slowing progression","volume":"46","author":"Naaman","year":"2023","journal-title":"Diabetes Care."},{"issue":"6","key":"B31-20260402","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1161\/CIRCULATIONAHA.123.067584","article-title":"Estimated lifetime cardiovascular, kidney, and mortality benefits of combination treatment with SGLT2 inhibitors, GLP-1 receptor agonists, and nonsteroidal MRA compared with conventional care in patients with type 2 diabetes and albuminuria","volume":"149","author":"Neuen","year":"2024","journal-title":"Circulation."},{"issue":"12","key":"B32-20260402","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1056\/NEJMoa011161","article-title":"Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy","volume":"345","author":"Brenner","year":"2001","journal-title":"N Engl J Med."},{"issue":"12","key":"B33-20260402","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1056\/NEJMoa011303","article-title":"Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes","volume":"345","author":"Lewis","year":"2001","journal-title":"N Engl J Med."},{"issue":"20","key":"B34-20260402","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1056\/NEJM199311113292004","article-title":"The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The collaborative study group","volume":"329","author":"Lewis","year":"1993","journal-title":"N Engl J Med."},{"issue":"20","key":"B35-20260402","doi-asserted-by":"crossref","first-page":"1892","DOI":"10.1056\/NEJMoa1303154","article-title":"Combined angiotensin inhibition for the treatment of diabetic nephropathy","volume":"369","author":"Fried","year":"2013","journal-title":"N Engl J Med."},{"issue":"5","key":"B36-20260402","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/j.tem.2021.02.002","article-title":"Finerenone: a nNon-steroidal mineralocorticoid receptor blocker for diabetic kidney disease","volume":"32","author":"Verma","year":"2021","journal-title":"Trends Endocrinol Metab."},{"issue":"6","key":"B37-20260402","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1093\/eurheartj\/ehab777","article-title":"Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysis","volume":"43","author":"Agarwal","year":"2022","journal-title":"Eur Heart J."},{"issue":"11","key":"B38-20260402","doi-asserted-by":"crossref","first-page":"2755","DOI":"10.1681\/ASN.2018010103","article-title":"Empagliflozin and kidney function decline in patients with type 2 diabetes: a slope analysis from the EMPA-REG OUTCOME trial","volume":"29","author":"Wanner","year":"2018","journal-title":"J Am Soc Nephrol."},{"issue":"4","key":"B39-20260402","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1056\/NEJMoa1515920","article-title":"Empagliflozin and progression of kidney disease in type 2 diabetes","volume":"375","author":"Wanner","year":"2016","journal-title":"N Engl J Med."},{"issue":"22","key":"B40-20260402","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","article-title":"Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes","volume":"373","author":"Zinman","year":"2015","journal-title":"N Engl J Med."},{"issue":"8","key":"B41-20260402","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1161\/CIRCULATIONAHA.123.065251","article-title":"Cardiorenal biomarkers, canagliflozin, and outcomes in diabetic kidney disease: the CREDENCE trial","volume":"148","author":"Januzzi","year":"2023","journal-title":"Circulation."},{"issue":"15","key":"B42-20260402","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1056\/NEJMoa2024816","article-title":"Dapagliflozin in patients with chronic kidney disease","volume":"383","author":"Heerspink","year":"2020","journal-title":"N Engl J Med."},{"issue":"4","key":"B43-20260402","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1093\/ndt\/gfae203","article-title":"Empagliflozin lowers serum uric acid in chronic kidney disease: exploratory analyses from the EMPA-KIDNEY trial","volume":"40","author":"Mayne","year":"2025","journal-title":"Nephrol Dial Transplant."},{"issue":"4","key":"B44-20260402","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.2337\/dc20-1622","article-title":"Changes in albuminuria predict cardiovascular and renal outcomes in type 2 diabetes: a post hoc analysis of the LEADER trial","volume":"44","author":"Persson","year":"2021","journal-title":"Diabetes Care."},{"key":"B45-20260402","doi-asserted-by":"crossref","first-page":"662775","DOI":"10.3389\/fmed.2021.662775","article-title":"Evaluation of consistency of treatment response across regions-the LEADER trial in relation to the ICH E17 guideline","volume":"8","author":"Nielsen","year":"2021","journal-title":"Front Med (Lausanne)."},{"issue":"11","key":"B46-20260402","doi-asserted-by":"crossref","first-page":"5157","DOI":"10.1111\/dom.15860","article-title":"Effect of semaglutide on primary prevention of diabetic kidney disease in people with type 2 diabetes: a post hoc analysis of the SUSTAIN 6 randomized controlled trial","volume":"26","author":"Wang","year":"2024","journal-title":"Diabetes Obes Metab."},{"issue":"9","key":"B47-20260402","doi-asserted-by":"crossref","first-page":"2041","DOI":"10.1093\/ndt\/gfad009","article-title":"The rationale, design and baseline data of FLOW, a kidney outcomes trial with once-weekly semaglutide in people with type 2 diabetes and chronic kidney disease","volume":"38","author":"Rossing","year":"2023","journal-title":"Nephrol Dial Transplant."},{"issue":"12","key":"B48-20260402","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1093\/eurheartj\/ehae613","article-title":"Cardiovascular outcomes with semaglutide by severity of chronic kidney disease in type 2 diabetes: the FLOW trial","volume":"46","author":"Mahaffey","year":"2025","journal-title":"Eur Heart J."},{"issue":"12","key":"B49-20260402","doi-asserted-by":"crossref","first-page":"2991","DOI":"10.2337\/dc22-0294","article-title":"Finerenone in patients with chronic kidney disease and type 2 diabetes by sodium-gSodium-Glucose cotransporter 2 inhibitor treatment: the FIDELITY analysis","volume":"45","author":"Rossing","year":"2022","journal-title":"Diabetes Care."},{"issue":"10","key":"B50-20260402","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1056\/NEJMoa2108269","article-title":"Cardiovascular and renal outcomes with efpeglenatide in type 2 diabetes","volume":"385","author":"Gerstein","year":"2021","journal-title":"N Engl J Med."},{"issue":"6","key":"B51-20260402","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1056\/NEJMoa2410659","article-title":"Finerenone with empagliflozin in chronic kidney disease and type 2 diabetes","volume":"393","author":"Agarwal","year":"2025","journal-title":"N Engl J Med."},{"issue":"suppl 1","key":"B52-20260402","doi-asserted-by":"crossref","first-page":"i59","DOI":"10.1093\/ndt\/gfae258","article-title":"Combination therapy as a new standard of care in diabetic and non-diabetic chronic kidney disease","volume":"40","author":"Neuen","year":"2025","journal-title":"Nephrol Dial Transplant."},{"issue":"9","key":"B53-20260402","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.2215\/CJN.0000000000000526","article-title":"Reframing chronicity with urgency in chronic kidney disease management","volume":"19","author":"Neuen","year":"2024","journal-title":"Clin J Am Soc Nephrol."},{"issue":"10184","key":"B54-20260402","doi-asserted-by":"crossref","first-page":"1937","DOI":"10.1016\/S0140-6736(19)30772-X","article-title":"Atrasentan and renal events in patients with type 2 diabetes and chronic kidney disease (SONAR): a double-blind, randomised, placebo-controlled trial","volume":"393","author":"Heerspink","year":"2019","journal-title":"Lancet."},{"issue":"2","key":"B55-20260402","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1016\/j.kint.2020.09.026","article-title":"New insights from SONAR indicate adding sodium glucose co-transporter 2 inhibitors to an endothelin receptor antagonist mitigates fluid retention and enhances albuminuria reduction","volume":"99","author":"Heerspink","year":"2021","journal-title":"Kidney Int."},{"issue":"10416","key":"B56-20260402","doi-asserted-by":"crossref","first-page":"2004","DOI":"10.1016\/S0140-6736(23)02230-4","article-title":"Zibotentan in combination with dapagliflozin compared with dapagliflozin in patients with chronic kidney disease (ZENITH-CKD): a multicentre, randomised, active-controlled, phase 2b, clinical trial","volume":"402","author":"Heerspink","year":"2023","journal-title":"Lancet."},{"issue":"6","key":"B57-20260402","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1093\/ndt\/gfae263","article-title":"The potential for improving cardio-renal outcomes in chronic kidney disease with the aldosterone synthase inhibitor vicadrostat (BI 690517): a rationale for the EASi-KIDNEY trial","volume":"40","author":"Judge","year":"2025","journal-title":"Nephrol Dial Transplant."},{"issue":"12","key":"B58-20260402","doi-asserted-by":"crossref","first-page":"1965","DOI":"10.1681\/ASN.0000000000000248","article-title":"Effect of SGLT2 inhibitors on discontinuation of renin-angiotensin system blockade: a joint analysis of the CREDENCE and DAPA-CKD trials","volume":"34","author":"Fletcher","year":"2023","journal-title":"J Am Soc Nephrol."},{"issue":"11","key":"B59-20260402","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1016\/j.jacc.2021.01.044","article-title":"Interplay of mineralocorticoid receptor antagonists and empagliflozin in heart failure: EMPEROR-reduced","volume":"77","author":"Ferreira","year":"2021","journal-title":"J Am Coll Cardiol."},{"issue":"1","key":"B60-20260402","doi-asserted-by":"crossref","first-page":"43315","DOI":"10.1038\/s41598-025-27239-8","article-title":"Triple therapy of RAS inhibitors, dapagliflozin, and finerenone in diabetic kidney disease patients with nephrotic-range proteinuria: a real-world study","volume":"15","author":"Gu","year":"2025","journal-title":"Sci Rep."},{"issue":"7","key":"B61-20260402","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1016\/j.jacc.2025.10.049","article-title":"Risk of hyperkalemia with empagliflozin, finerenone, or both: secondary analysis of the CONFIDENCE randomized trial","volume":"87","author":"Agarwal","year":"2026","journal-title":"J Am Coll Cardiol."},{"issue":"2","key":"B62-20260402","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1681\/ASN.2021070948","article-title":"Acute treatment effects on GFR in randomized clinical trials of kidney disease progression","volume":"33","author":"Neuen","year":"2022","journal-title":"J Am Soc Nephrol."},{"issue":"8012","key":"B63-20260402","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1038\/s41586-024-07316-0","article-title":"Refining the impact of genetic evidence on clinical success","volume":"629","author":"Minikel","year":"2024","journal-title":"Nature."},{"issue":"2","key":"B64-20260402","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1681\/ASN.2016020231","article-title":"The genetic landscape of renal complications in type 1 diabetes","volume":"28","author":"Sandholm","year":"2017","journal-title":"J Am Soc Nephrol."},{"issue":"6","key":"B65-20260402","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1007\/s00125-014-3202-3","article-title":"Genome-wide association study of urinary albumin excretion rate in patients with type 1 diabetes","volume":"57","author":"Sandholm","year":"2014","journal-title":"Diabetologia."},{"issue":"10","key":"B66-20260402","doi-asserted-by":"crossref","first-page":"1939","DOI":"10.1681\/ASN.0000000718","article-title":"Genome-wide association study of quantitative kidney function in 52,531 individuals with diabetes identifies five diabetes-specific loci","volume":"36","author":"Cole","year":"2025","journal-title":"J Am Soc Nephrol."},{"issue":"1","key":"B67-20260402","doi-asserted-by":"crossref","first-page":"2543","DOI":"10.1038\/s41467-023-37837-7","article-title":"DNA methylation markers for kidney function and progression of diabetic kidney disease","volume":"14","author":"Li","year":"2023","journal-title":"Nat Commun."},{"issue":"6","key":"B68-20260402","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1038\/s41581-019-0135-6","article-title":"Epigenetics and epigenomics in diabetic kidney disease and metabolic memory","volume":"15","author":"Kato","year":"2019","journal-title":"Nat Rev Nephrol."},{"issue":"11","key":"B69-20260402","doi-asserted-by":"crossref","first-page":"1496","DOI":"10.1038\/nm.3363","article-title":"Renal tubular Sirt1 attenuates diabetic albuminuria by epigenetically suppressing Claudin-1 overexpression in podocytes","volume":"19","author":"Hasegawa","year":"2013","journal-title":"Nat Med."},{"issue":"1","key":"B70-20260402","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1186\/s43556-025-00253-y","article-title":"Klotho antiaging protein: molecular mechanisms and therapeutic potential in diseases","volume":"6","author":"Hajare","year":"2025","journal-title":"Mol Biomed."},{"issue":"1","key":"B71-20260402","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1186\/s10020-021-00365-5","article-title":"METTL14 promotes glomerular endothelial cell injury and diabetic nephropathy via m6A modification of alpha-klotho","volume":"27","author":"Li","year":"2021","journal-title":"Mol Med."},{"issue":"7","key":"B72-20260402","doi-asserted-by":"crossref","first-page":"1648","DOI":"10.1681\/ASN.2014070678","article-title":"Myocardin-related transcription factor A epigenetically regulates renal fibrosis in diabetic nephropathy","volume":"26","author":"Xu","year":"2015","journal-title":"J Am Soc Nephrol."},{"issue":"1","key":"B73-20260402","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1172\/JCI95946","article-title":"Shifts in podocyte histone H3K27me3 regulate mouse and human glomerular disease","volume":"128","author":"Majumder","year":"2018","journal-title":"J Clin Invest."},{"issue":"7","key":"B74-20260402","doi-asserted-by":"crossref","first-page":"2021","DOI":"10.1681\/ASN.2014090898","article-title":"The histone methyltransferase enzyme enhancer of zeste homolog 2 protects against podocyte oxidative stress and renal injury in diabetes","volume":"27","author":"Siddiqi","year":"2016","journal-title":"J Am Soc Nephrol."},{"issue":"8","key":"B75-20260402","doi-asserted-by":"crossref","first-page":"3485","DOI":"10.1016\/j.ymthe.2025.04.026","article-title":"Histone deacetylases and their inhibitors in kidney diseases","volume":"33","author":"Zheng","year":"2025","journal-title":"Mol Ther."},{"key":"B76-20260402","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.3389\/fphar.2019.01393","article-title":"Histone methyltransferases as therapeutic targets for kidney diseases","volume":"10","author":"Yu","year":"2019","journal-title":"Front Pharmacol."},{"issue":"12","key":"B77-20260402","doi-asserted-by":"crossref","first-page":"4577","DOI":"10.1111\/bcp.14889","article-title":"Recent developments of HDAC inhibitors: emerging indications and novel molecules","volume":"87","author":"Bondarev","year":"2021","journal-title":"Br J Clin Pharmacol."},{"issue":"4","key":"B78-20260402","doi-asserted-by":"crossref","first-page":"F716","DOI":"10.1152\/ajprenal.00314.2016","article-title":"Immunity and inflammation in diabetic kidney disease: translating mechanisms to biomarkers and treatment targets","volume":"312","author":"Pichler","year":"2017","journal-title":"Am J Physiol Renal Physiol."},{"issue":"1","key":"B79-20260402","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1080\/13813455.2020.1797106","article-title":"Role of advanced glycation end products and insulin resistance in diabetic nephropathy","volume":"129","author":"Parwani","year":"2023","journal-title":"Arch Physiol Biochem."},{"issue":"40","key":"B80-20260402","doi-asserted-by":"crossref","first-page":"37264","DOI":"10.1021\/acsomega.3c05085","article-title":"Crosstalk between aldosterone and glycation through Rac-1 induces diabetic nephropathy","volume":"8","author":"Apte","year":"2023","journal-title":"ACS Omega."},{"issue":"1","key":"B81-20260402","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1186\/s12944-017-0522-6","article-title":"Advanced glycation end products (AGEs) increase renal lipid accumulation: a pathogenic factor of diabetic nephropathy (DN)","volume":"16","author":"Yuan","year":"2017","journal-title":"Lipids Health Dis."},{"issue":"1","key":"B82-20260402","doi-asserted-by":"crossref","first-page":"225","DOI":"10.2337\/diabetes.55.01.06.db05-0894","article-title":"Glucose-induced reactive oxygen species cause apoptosis of podocytes and podocyte depletion at the onset of diabetic nephropathy","volume":"55","author":"Susztak","year":"2006","journal-title":"Diabetes."},{"key":"B83-20260402","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1016\/j.freeradbiomed.2021.05.025","article-title":"AGE\/RAGE in diabetic kidney disease and ageing kidney","volume":"171","author":"Wu","year":"2021","journal-title":"Free Radic Biol Med."},{"issue":"1","key":"B84-20260402","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1038\/ki.2014.322","article-title":"Revisiting inflammation in diabetic nephropathy: the role of the Nlrp3 inflammasome in glomerular resident cells","volume":"87","author":"Sakai","year":"2015","journal-title":"Kidney Int."},{"issue":"10","key":"B85-20260402","doi-asserted-by":"crossref","first-page":"578","DOI":"10.3390\/toxins11100578","article-title":"Endothelial toxicity of high glucose and its by-Products in diabetic kidney disease","volume":"11","author":"Dou","year":"2019","journal-title":"Toxins (Basel)."},{"issue":"1","key":"B86-20260402","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1159\/000075627","article-title":"Randomized trial of an inhibitor of formation of advanced glycation end products in diabetic nephropathy","volume":"24","author":"Bolton","year":"2004","journal-title":"Am J Nephrol."},{"issue":"5","key":"B87-20260402","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1016\/S0197-2456(99)00024-0","article-title":"Design and baseline characteristics for the aminoguanidine clinical trial in overt type 2 diabetic nephropathy (ACTION II)","volume":"20","author":"Freedman","year":"1999","journal-title":"Control Clin Trials."},{"issue":"6","key":"B88-20260402","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1159\/000108104","article-title":"Effects of pyridoxamine in combined phase 2 studies of patients with type 1 and type 2 diabetes and overt nephropathy","volume":"27","author":"Williams","year":"2007","journal-title":"Am J Nephrol."},{"issue":"6","key":"B89-20260402","doi-asserted-by":"crossref","first-page":"1683","DOI":"10.2337\/db16-1281","article-title":"RAGE-aptamer blocks the development and progression of experimental diabetic nephropathy","volume":"66","author":"Matsui","year":"2017","journal-title":"Diabetes."},{"issue":"11","key":"B90-20260402","doi-asserted-by":"crossref","first-page":"F1276","DOI":"10.1152\/ajprenal.00396.2014","article-title":"Targeting NADPH oxidase with a novel dual Nox1\/Nox4 inhibitor attenuates renal pathology in type 1 diabetes","volume":"308","author":"Gorin","year":"2015","journal-title":"Am J Physiol Renal Physiol."},{"issue":"5","key":"B91-20260402","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1007\/s00125-017-4215-5","article-title":"Combined NOX1\/4 inhibition with GKT137831 in mice provides dose-dependent reno- and atheroprotection even in established micro- and macrovascular disease","volume":"60","author":"Gray","year":"2017","journal-title":"Diabetologia."},{"issue":"1","key":"B92-20260402","doi-asserted-by":"crossref","first-page":"4407","DOI":"10.1038\/s41598-018-36344-w","article-title":"AKF-PD alleviates diabetic nephropathy via blocking the RAGE\/AGEs\/NOX and PKC\/NOX pathways","volume":"9","author":"Qin","year":"2019","journal-title":"Sci Rep."},{"issue":"7","key":"B93-20260402","doi-asserted-by":"crossref","first-page":"1775","DOI":"10.1016\/j.ekir.2021.04.023","article-title":"Chronic inflammation in chronic kidney disease progression: role of Nrf2","volume":"6","author":"Stenvinkel","year":"2021","journal-title":"Kidney Int Rep."},{"issue":"4","key":"B94-20260402","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1056\/NEJMoa1105351","article-title":"Bardoxolone methyl and kidney function in CKD with type 2 diabetes","volume":"365","author":"Pergola","year":"2011","journal-title":"N Engl J Med."},{"issue":"26","key":"B95-20260402","doi-asserted-by":"crossref","first-page":"2492","DOI":"10.1056\/NEJMoa1306033","article-title":"Bardoxolone methyl in type 2 diabetes and stage 4 chronic kidney disease","volume":"369","author":"de Zeeuw","year":"2013","journal-title":"N Engl J Med."},{"issue":"5","key":"B96-20260402","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1093\/ndt\/gfac242","article-title":"Randomized, double-blind, placebo-controlled phase 3 study of bardoxolone methyl in patients with diabetic kidney disease: design and baseline characteristics of the AYAME study","volume":"38","author":"Nangaku","year":"2023","journal-title":"Nephrol Dial Transplant."},{"issue":"10","key":"B97-20260402","doi-asserted-by":"crossref","first-page":"4026","DOI":"10.7150\/ijbs.73493","article-title":"AKAP1 contributes to impaired mtDNA replication and mitochondrial dysfunction in podocytes of diabetic kidney disease","volume":"18","author":"Feng","year":"2022","journal-title":"Int J Biol Sci."},{"issue":"13","key":"B98-20260402","doi-asserted-by":"crossref","first-page":"e33366","DOI":"10.1097\/MD.0000000000033366","article-title":"Management of diabetic kidney disease: where do we stand?: a narrative review","volume":"102","author":"Sindhu","year":"2023","journal-title":"Medicine (Baltimore)."},{"issue":"7","key":"B99-20260402","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1053\/meta.2001.24207","article-title":"High glucose stimulates hyaluronan production by renal interstitial fibroblasts through the protein kinase C and transforming growth factor-beta cascade","volume":"50","author":"Takeda","year":"2001","journal-title":"Metabolism."},{"issue":"2","key":"B100-20260402","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1111\/j.1464-410X.2011.10805.x","article-title":"Protein kinase C inhibitor prevents renal apoptotic and fibrotic changes in response to partial ureteric obstruction","volume":"110","author":"Juan","year":"2012","journal-title":"BJU Int."},{"issue":"5","key":"B101-20260402","doi-asserted-by":"crossref","first-page":"1643","DOI":"10.1172\/JCI115179","article-title":"Elevated glucose impairs endothelium-dependent relaxation by activating protein kinase C","volume":"87","author":"Tesfamariam","year":"1991","journal-title":"J Clin Invest."},{"issue":"7","key":"B102-20260402","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1681\/ASN.2009070760","article-title":"PKC-delta promotes renal tubular cell apoptosis associated with proteinuria","volume":"21","author":"Li","year":"2010","journal-title":"J Am Soc Nephrol."},{"issue":"4","key":"B103-20260402","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1053\/j.ajkd.2014.11.024","article-title":"Effect of ruboxistaurin on albuminuria and estimated GFR in people with diabetic peripheral neuropathy: results from a randomized trial","volume":"65","author":"Tuttle","year":"2015","journal-title":"Am J Kidney Dis."},{"issue":"4","key":"B104-20260402","doi-asserted-by":"crossref","first-page":"631","DOI":"10.2215\/CJN.00840207","article-title":"Kidney outcomes in long-term studies of ruboxistaurin for diabetic eye disease","volume":"2","author":"Tuttle","year":"2007","journal-title":"Clin J Am Soc Nephrol."},{"issue":"1","key":"B105-20260402","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1681\/ASN.0000000000000245","article-title":"Effect of ziltivekimab on determinants of hemoglobin in patients with CKD stage 3-5: an analysis of a randomized trial (RESCUE)","volume":"35","author":"Pergola","year":"2024","journal-title":"J Am Soc Nephrol."},{"issue":"10289","key":"B106-20260402","doi-asserted-by":"crossref","first-page":"2060","DOI":"10.1016\/S0140-6736(21)00520-1","article-title":"IL-6 inhibition with ziltivekimab in patients at high atherosclerotic risk (RESCUE): a double-blind, randomised, placebo-controlled, phase 2 trial","volume":"397","author":"Ridker","year":"2021","journal-title":"Lancet."},{"issue":"14","key":"B107-20260402","doi-asserted-by":"crossref","first-page":"3393","DOI":"10.3390\/ijms20143393","article-title":"Unraveling the role of inflammation in the pathogenesis of diabetic kidney disease","volume":"20","author":"Matoba","year":"2019","journal-title":"Int J Mol Sci."},{"issue":"4","key":"B108-20260402","doi-asserted-by":"crossref","first-page":"1492","DOI":"10.1046\/j.1523-1755.2000.00311.x","article-title":"Up-regulation of monocyte chemoattractant protein-1 in tubulointerstitial lesions of human diabetic nephropathy","volume":"58","author":"Wada","year":"2000","journal-title":"Kidney Int."},{"issue":"1","key":"B109-20260402","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1681\/ASN.2020040487","article-title":"Association of multiple plasma biomarker concentrations with progression of prevalent diabetic kidney disease: findings from the Chronic Renal Insufficiency Cohort (CRIC) study","volume":"32","author":"Schrauben","year":"2021","journal-title":"J Am Soc Nephrol."},{"issue":"2","key":"B110-20260402","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1093\/ndt\/gfv459","article-title":"C-C motif-ligand 2 inhibition with emapticap pegol (NOX-E36) in type 2 diabetic patients with albuminuria","volume":"32","author":"Menne","year":"2017","journal-title":"Nephrol Dial Transplant."},{"issue":"9","key":"B111-20260402","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1016\/S2213-8587(15)00261-2","article-title":"The effect of CCR2 inhibitor CCX140-B on residual albuminuria in patients with type 2 diabetes and nephropathy: a randomised trial","volume":"3","author":"de Zeeuw","year":"2015","journal-title":"Lancet Diabetes Endocrinol."},{"issue":"6","key":"B112-20260402","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1016\/j.ekir.2018.07.010","article-title":"Effect of PF-04634817, an oral CCR2\/5 chemokine receptor antagonist, on albuminuria in adults with overt diabetic nephropathy","volume":"3","author":"Gale","year":"2018","journal-title":"Kidney Int Rep."},{"issue":"2","key":"B113-20260402","doi-asserted-by":"crossref","first-page":"469","DOI":"10.2337\/db08-1328","article-title":"Enhanced expression of Janus Kinase-signal transducer and activator of transcription pathway members in human diabetic nephropathy","volume":"58","author":"Berthier","year":"2009","journal-title":"Diabetes."},{"issue":"11","key":"B114-20260402","doi-asserted-by":"crossref","first-page":"1950","DOI":"10.1093\/ndt\/gfx377","article-title":"JAK1\/JAK2 inhibition by baricitinib in diabetic kidney disease: results from a phase 2 randomized controlled clinical trial","volume":"33","author":"Tuttle","year":"2018","journal-title":"Nephrol Dial Transplant."},{"issue":"4","key":"B115-20260402","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1016\/j.kint.2017.03.027","article-title":"Podocyte-specific JAK2 overexpression worsens diabetic kidney disease in mice","volume":"92","author":"Zhang","year":"2017","journal-title":"Kidney Int."},{"key":"B116-20260402","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.cca.2018.03.033","article-title":"Lectin-induced renal local complement activation is involved in tubular interstitial injury in diabetic nephropathy","volume":"482","author":"Zheng","year":"2018","journal-title":"Clin Chim Acta."},{"issue":"5","key":"B117-20260402","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1111\/jdi.13739","article-title":"Activation of complement C1q and C3 in glomeruli might accelerate the progression of diabetic nephropathy: evidence from transcriptomic data and renal histopathology","volume":"13","author":"Jiao","year":"2022","journal-title":"J Diabetes Investig."},{"key":"B118-20260402","doi-asserted-by":"crossref","first-page":"868127","DOI":"10.3389\/fimmu.2022.868127","article-title":"Complement deposition predicts worsening kidney function and underlines the clinical significance of the 2010 renal pathology society classification of diabetic nephropathy","volume":"13","author":"Jiang","year":"2022","journal-title":"Front Immunol."},{"key":"B119-20260402","doi-asserted-by":"crossref","first-page":"504","DOI":"10.3389\/fimmu.2019.00504","article-title":"The emerging role of complement proteins as a target for therapy of IgA nephropathy","volume":"10","author":"Rizk","year":"2019","journal-title":"Front Immunol."},{"key":"B120-20260402","doi-asserted-by":"crossref","first-page":"2166","DOI":"10.3389\/fimmu.2019.02166","article-title":"Complement inhibitors in clinical trials for glomerular diseases","volume":"10","author":"Zipfel","year":"2019","journal-title":"Front Immunol."},{"issue":"6","key":"B121-20260402","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1056\/NEJMoa2410316","article-title":"Alternative complement pathway inhibition with iptacopan in IgA nephropathy","volume":"392","author":"Perkovic","year":"2025","journal-title":"N Engl J Med."},{"issue":"11","key":"B122-20260402","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1056\/NEJMoa2029073","article-title":"Pegcetacoplan versus eculizumab in paroxysmal nocturnal hemoglobinuria","volume":"384","author":"Hillmen","year":"2021","journal-title":"N Engl J Med."},{"issue":"suppl 2","key":"B123-20260402","doi-asserted-by":"crossref","first-page":"ii29","DOI":"10.1093\/ndt\/gfad079","article-title":"Complement inhibitors for kidney disease","volume":"38","author":"Wooden","year":"2023","journal-title":"Nephrol Dial Transplant."},{"key":"B124-20260402","doi-asserted-by":"crossref","first-page":"661076","DOI":"10.3389\/fmed.2021.661076","article-title":"Update on the mechanisms of tubular cell injury in diabetic kidney disease","volume":"8","author":"Chang","year":"2021","journal-title":"Front Med (Lausanne)."},{"issue":"2","key":"B125-20260402","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1093\/ndt\/gfw443","article-title":"Interstitial fibrosis scored on whole-slide digital imaging of kidney biopsies is a predictor of outcome in proteinuric glomerulopathies","volume":"33","author":"Mariani","year":"2018","journal-title":"Nephrol Dial Transplant."},{"issue":"1","key":"B126-20260402","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1186\/s12967-025-06554-8","article-title":"Uncovering key markers and therapeutic targets for renal fibrosis in diabetic kidney disease through bulk and single-cell RNA sequencing","volume":"23","author":"Li","year":"2025","journal-title":"J Transl Med."},{"key":"B127-20260402","doi-asserted-by":"crossref","first-page":"21","DOI":"10.12703\/r\/11-21","article-title":"AKI-to-CKD transition is a potential mechanism for non-albuminuric diabetic kidney disease","volume":"11","author":"Lee","year":"2022","journal-title":"Fac Rev."},{"key":"B128-20260402","doi-asserted-by":"crossref","first-page":"82","DOI":"10.3389\/fphys.2015.00082","article-title":"TGF-beta\/Smad signaling in renal fibrosis","volume":"6","author":"Meng","year":"2015","journal-title":"Front Physiol."},{"issue":"6","key":"B129-20260402","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1681\/ASN.2010101049","article-title":"Pirfenidone for diabetic nephropathy","volume":"22","author":"Sharma","year":"2011","journal-title":"J Am Soc Nephrol."},{"issue":"Pt 1","key":"B130-20260402","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1042\/bj3590077","article-title":"Role of connective tissue growth factor in the pathogenesis of diabetic nephropathy","volume":"359","author":"Wahab","year":"2001","journal-title":"Biochem J."},{"issue":"6","key":"B131-20260402","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.2337\/dc07-2469","article-title":"Plasma connective tissue growth factor is an independent predictor of end-stage renal disease and mortality in type 1 diabetic nephropathy","volume":"31","author":"Nguyen","year":"2008","journal-title":"Diabetes Care."},{"issue":"8","key":"B132-20260402","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1038\/ncb826","article-title":"Connective-tissue growth factor (CTGF) modulates cell signalling by BMP and TGF-beta","volume":"4","author":"Abreu","year":"2002","journal-title":"Nat Cell Biol."},{"issue":"8","key":"B133-20260402","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.2215\/CJN.09321209","article-title":"Phase 1 study of anti-CTGF monoclonal antibody in patients with diabetes and microalbuminuria","volume":"5","author":"Adler","year":"2010","journal-title":"Clin J Am Soc Nephrol."},{"issue":"4","key":"B134-20260402","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.7150\/ijbs.101548","article-title":"Modulation of TGF-beta signaling new approaches toward kidney disease and fibrosis therapy","volume":"21","author":"Hong","year":"2025","journal-title":"Int J Biol Sci."},{"issue":"4","key":"B135-20260402","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1038\/nm.2685","article-title":"A systems approach identifies HIPK2 as a key regulator of kidney fibrosis","volume":"18","author":"Jin","year":"2012","journal-title":"Nat Med."},{"issue":"7","key":"B136-20260402","doi-asserted-by":"crossref","first-page":"2133","DOI":"10.1681\/ASN.2016080841","article-title":"A novel inhibitor of homeodomain interacting protein kinase 2 mitigates kidney fibrosis through inhibition of the TGF-beta1\/Smad3 pathway","volume":"28","author":"Liu","year":"2017","journal-title":"J Am Soc Nephrol."},{"issue":"6","key":"B137-20260402","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1681\/ASN.0000000000000327","article-title":"Small molecule allosteric inhibitor of HIPK2 as a novel therapy against kidney fibrosis","volume":"35","author":"Lee","year":"2024","journal-title":"J Am Soc Nephrol."},{"key":"B138-20260402","first-page":"8833725","article-title":"Mesenchymal stem cell therapy for diabetic kidney disease: a review of the studies using syngeneic, autologous, allogeneic, and xenogeneic cells","volume":"2020","author":"Savio-Silva","year":"2020","journal-title":"Stem Cell Int."},{"issue":"4","key":"B139-20260402","doi-asserted-by":"crossref","first-page":"1546","DOI":"10.3390\/ijms22041546","article-title":"Therapeutic potential of mesenchymal stem cells in a pre-clinical model of diabetic kidney disease and obesity","volume":"22","author":"Savio-Silva","year":"2021","journal-title":"Int J Mol Sci."},{"issue":"4","key":"B140-20260402","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1007\/s00109-024-02432-w","article-title":"The therapeutic effect of mesenchymal stem cells in diabetic kidney disease","volume":"102","author":"Habiba","year":"2024","journal-title":"J Mol Med (Berl)."},{"issue":"4","key":"B141-20260402","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1093\/stmcls\/sxad010","article-title":"Mesenchymal stem cell-derived exosomes ameliorate diabetic kidney disease through the NLRP3 signaling pathway","volume":"41","author":"Wang","year":"2023","journal-title":"Stem Cells."},{"issue":"9","key":"B142-20260402","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1002\/sctm.19-0419","article-title":"A systematic review and meta-analysis of cell-based interventions in experimental diabetic kidney disease","volume":"10","author":"Hickson","year":"2021","journal-title":"Stem Cell Transl Med."},{"issue":"1","key":"B143-20260402","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1186\/s13287-020-02108-5","article-title":"Administration of mesenchymal stem cells in diabetic kidney disease: a systematic review and meta-analysis","volume":"12","author":"Lin","year":"2021","journal-title":"Stem Cell Res Ther."},{"issue":"10","key":"B144-20260402","doi-asserted-by":"crossref","first-page":"1733","DOI":"10.1681\/ASN.0000000000000189","article-title":"Safety and preliminary efficacy of mesenchymal stromal cell (ORBCEL-M) therapy in diabetic kidney disease: a randomized clinical trial (NEPHSTROM)","volume":"34","author":"Perico","year":"2023","journal-title":"J Am Soc Nephrol."},{"issue":"Pt 3","key":"B145-20260402","doi-asserted-by":"crossref","first-page":"146353","DOI":"10.1016\/j.ijbiomac.2025.146353","article-title":"Fibronectin-assisted reactive oxygen species-responsive mesoporous silica-loaded epigallocatechin-3-gallate for treating diabetic nephropathy by enhancing autophagy and regulating M1-type macrophage polarization","volume":"321","author":"Li","year":"2025","journal-title":"Int J Biol Macromol."},{"key":"B146-20260402","doi-asserted-by":"crossref","first-page":"102856","DOI":"10.1016\/j.nano.2025.102856","article-title":"A novel treatment for diabetic nephropathy: folate receptor-targeted delivery of TLR4 siRNA via functionalized PLGA nanoparticles in streptozotocin-induced diabetic murine models","volume":"69","author":"Wang","year":"2025","journal-title":"Nanomedicine."},{"issue":"18","key":"B147-20260402","doi-asserted-by":"crossref","first-page":"e71045","DOI":"10.1096\/fj.202501936R","article-title":"Stem cell membrane biomimetic nano-formulation achieves the delivery of MKP5 to ameliorate diabetic kidney disease via the P38 and ERK pathway","volume":"39","author":"Sun","year":"2025","journal-title":"FASEB J."},{"issue":"1","key":"B148-20260402","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1186\/s12951-025-03108-4","article-title":"RGD-HSA-TAC nanoparticles targeted delivery of tacrolimus and attenuation of podocyte injury in diabetic kidney disease","volume":"23","author":"Guo","year":"2025","journal-title":"J Nanobiotechnology."},{"issue":"10424","key":"B149-20260402","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/S0140-6736(23)02408-X","article-title":"Efficacy and safety of aldosterone synthase inhibition with and without empagliflozin for chronic kidney disease: a randomised, controlled, phase 2 trial","volume":"403","author":"Tuttle","year":"2024","journal-title":"Lancet."},{"issue":"9","key":"B150-20260402","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1681\/ASN.0000000000000418","article-title":"Effect of avenciguat on albuminuria in patients with CKD: two randomized placebo-controlled trials","volume":"35","author":"Heerspink","year":"2024","journal-title":"J Am Soc Nephrol."}],"container-title":["Clinical Journal of the American Society of Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.2215\/CJN.0000001053","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T13:45:51Z","timestamp":1786369551000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.2215\/CJN.0000001053"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,10]]},"references-count":150,"URL":"https:\/\/doi.org\/10.2215\/cjn.0000001053","relation":{},"ISSN":["1555-9041","1555-905X"],"issn-type":[{"value":"1555-9041","type":"print"},{"value":"1555-905X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,10]]}}}